KCPG
DGX icon

Kavar Capital Partners Group’s Quest Diagnostics DGX Stock Holding History

Kavar Capital Partners Group’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.42M Sell
11,415
-943
-8% -$185K 0.3% 70
2026
Q1 		$2.42M Sell
12,358
-345
-3% -$67K 0.3% 71
2025
Q4 		$2.2M Buy
12,703
+10
+0.1% +$1.82K 0.3% 66
2025
Q3 		$2.42M Hold
12,693
– – 0.32% 68
2025
Q2 		$2.28M Sell
12,693
-450
-3% -$78.2K 0.33% 69
2025
Q1 		$2.22M Hold
13,143
– – 0.37% 66
2024
Q4 		$1.98M Hold
13,143
– – 0.34% 70
2024
Q3 		$2.04M Sell
13,143
-700
-5% -$105K 0.32% 72
2024
Q2 		$1.89M Sell
13,843
-200
-1% -$27.4K 0.34% 69
2024
Q1 		$1.87M Sell
14,043
-14,903
-51% -$1.93M 0.35% 70
2023
Q4 		$3.99M Buy
28,946
+14,223
+97% +$1.87M 0.45% 60
2023
Q3 		$1.79M Sell
14,723
-771
-5% -$103K 0.39% 68
2023
Q2 		$2.18M Sell
15,494
-2,495
-14% -$344K 0.46% 59
2023
Q1 		$2.55M Sell
17,989
-750
-4% -$107K 0.55% 56
2022
Q4 		$2.93M Sell
18,739
-702
-4% -$101K 0.68% 48
2022
Q3 		$2.38M Hold
19,441
– – 0.61% 50
2022
Q2 		$2.58M Sell
19,441
-170
-0.9% -$23.2K 0.6% 49
2022
Q1 		$2.68M Sell
19,611
-379
-2% -$52.8K 0.58% 50
2021
Q4 		$3.46M Buy
19,990
+415
+2% +$63.1K 0.72% 43
2021
Q3 		$2.84M Sell
19,575
-125
-0.6% -$18.3K 0.65% 47
2021
Q2 		$2.6M Buy
19,700
+300
+2% +$39.3K 0.63% 49
2021
Q1 		$2.49M Sell
19,400
-1,550
-7% -$191K 0.67% 46
2020
Q4 		$2.5M Hold
20,950
– – 0.72% 44
2020
Q3 		$2.4M Sell
20,950
-275
-1% -$32.5K 0.81% 42
2020
Q2 		$2.42M Hold
21,225
– – 0.93% 34
2020
Q1 		$1.7M Sell
21,225
-1,575
-7% -$163K 0.82% 46
2019
Q4 		$2.44M Buy
22,800
+400
+2% +$41.7K 0.9% 40
2019
Q3 		$2.4M Hold
22,400
– – 0.94% 41
2019
Q2 		$2.28M Buy
22,400
+1,100
+5% +$106K 0.9% 43
2019
Q1 		$1.92M Buy
21,300
+2,000
+10% +$173K 0.85% 46
2018
Q4 		$1.61M Buy
19,300
+2,650
+16% +$248K 0.87% 49
2018
Q3 		$1.8M Hold
16,650
– – 0.89% 49
2018
Q2 		$1.83M Sell
16,650
-325
-2% -$33.9K 0.92% 45
2018
Q1 		$1.7M Sell
16,975
-650
-4% -$66.6K 0.89% 47
2017
Q4 		$1.74M Sell
17,625
-250
-1% -$23.7K 0.92% 48
2017
Q3 		$1.67M Sell
17,875
-350
-2% -$37.2K 0.92% 53
2017
Q2 		$2.03M Sell
18,225
-250
-1% -$26.4K 1.1% 40
2017
Q1 		$1.81M Sell
18,475
-950
-5% -$90.6K 1.01% 46
2016
Q4 		$1.78M Sell
19,425
-350
-2% -$30.2K 1.13% 38
2016
Q3 		$1.67M Sell
19,775
-200
-1% -$16.8K 1.08% 45
2016
Q2 		$1.63M Sell
19,975
-200
-1% -$15.2K 1.05% 48
2016
Q1 		$1.44M Buy
20,175
+1,200
+6% +$80.5K 0.95% 53
2015
Q4 		$1.35M Buy
18,975
+600
+3% +$40.3K 0.87% 52
2015
Q3 		$1.13M Sell
18,375
-400
-2% -$28K 0.8% 56
2015
Q2 		$1.36M Buy
18,775
+600
+3% +$44.3K 0.92% 46
2015
Q1 		$1.4M Sell
18,175
-150
-0.8% -$10.7K 1.19% 38
2014
Q4 		$1.23M Buy
18,325
+50
+0.3% +$3.15K 0.97% 45
2014
Q3 		$1.11M Buy
18,275
+1,550
+9% +$95.5K 0.95% 46
2014
Q2 		$982K Buy
16,725
+1,000
+6% +$58.6K 0.83% 54
2014
Q1 		$910K Buy
15,725
+1,225
+8% +$65.7K 0.75% 54
2013
Q4 		$776K Buy
+14,500
New +$860K 0.69% 60

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Kavar Capital Partners Group's DGX Position: Q2 2026 in Review

Kavar Capital Partners Group reduced its Quest Diagnostics (DGX) stake by 7.6% in Q2 2026, selling an estimated $185K and leaving 11,415 shares worth $2.42M. The position accounts for 0.3% of the portfolio, ranked #70.

Kavar Capital Partners Group first reported a position in DGX in Q4 2013 and has held it in 51 quarters since. The position peaked at $3.99M in Q4 2023. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Kavar Capital Partners Group held 11,415 shares of Quest Diagnostics worth $2.42M as of Q2 2026.
  • Kavar Capital Partners Group sold 943 Quest Diagnostics shares in Q2 2026, an estimated $185K.
  • Quest Diagnostics made up 0.3% of Kavar Capital Partners Group's portfolio in Q2 2026, its #70 holding.
  • Kavar Capital Partners Group first reported a position in Quest Diagnostics in Q4 2013 and has held it in 51 quarters since.
  • Kavar Capital Partners Group's Quest Diagnostics position peaked at $3.99M in Q4 2023.
  • 1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Kavar Capital Partners Group's 13F filing for Q2 2026, filed 20 Jul 2026.